Page last updated: 2024-10-26

dipyridamole and Chronic Hepatitis C

dipyridamole has been researched along with Chronic Hepatitis C in 4 studies

Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.

Research Excerpts

ExcerptRelevanceReference
"Hemolysis is a frequent adverse effect of ribavirin (RBV)."9.11Low membrane protein sulfhydrils but not G6PD deficiency predict ribavirin-induced hemolysis in hepatitis C. ( Bihl, F; Grattagliano, I; Jüni, P; Lauterburg, BH; Palasciano, G; Palmieri, VO; Portincasa, P; Russmann, S, 2004)
"Hemolysis is a frequent adverse effect of ribavirin (RBV)."5.11Low membrane protein sulfhydrils but not G6PD deficiency predict ribavirin-induced hemolysis in hepatitis C. ( Bihl, F; Grattagliano, I; Jüni, P; Lauterburg, BH; Palasciano, G; Palmieri, VO; Portincasa, P; Russmann, S, 2004)
"Today, treatment of chronic hepatitis C is based on a synergistic combination of pegylated interferon and ribavirin with antiprotease inhibitors."3.78A new tool to study ribavirin-induced haemolysis. ( Brochot, E; Capron, D; Castelain, S; Duchaussoy, I; Duverlie, G; François, C; Helle, F; Nguyen-Khac, E; Van Nhien, AN, 2012)

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (25.00)18.2507
2000's2 (50.00)29.6817
2010's1 (25.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Brochot, E1
François, C1
Castelain, S1
Helle, F1
Van Nhien, AN1
Duchaussoy, I1
Capron, D1
Nguyen-Khac, E1
Duverlie, G1
Grattagliano, I1
Russmann, S1
Palmieri, VO1
Jüni, P1
Bihl, F1
Portincasa, P1
Palasciano, G1
Lauterburg, BH1
Iagoda, AV1
Koroĭ, PV1
Horino, T1
Kuriyama, S1
Tomonari, H1
Numata, M1
Hayashi, F1
Nagata, H1
Hikita, M1
Utsunomiya, Y1
Kawamura, T1
Hosoya, T1

Trials

1 trial available for dipyridamole and Chronic Hepatitis C

ArticleYear
Low membrane protein sulfhydrils but not G6PD deficiency predict ribavirin-induced hemolysis in hepatitis C.
    Hepatology (Baltimore, Md.), 2004, Volume: 39, Issue:5

    Topics: Adult; Antiviral Agents; Cell Membrane; Dipyridamole; Erythrocytes; Female; Glutathione; Glutathione

2004

Other Studies

3 other studies available for dipyridamole and Chronic Hepatitis C

ArticleYear
A new tool to study ribavirin-induced haemolysis.
    Antiviral therapy, 2012, Volume: 17, Issue:7

    Topics: Adenosine Triphosphate; Adult; Anemia, Hemolytic; Dipyridamole; Drug Evaluation, Preclinical; Drug T

2012
[Thrombocytic dysfunctions and potentialities of their differential correction in chronic viral hepatitis].
    Klinicheskaia meditsina, 2004, Volume: 82, Issue:10

    Topics: Adolescent; Adult; Antiviral Agents; Blood Platelets; Chronic Disease; Dipyridamole; Female; Hepatit

2004
[Renal damage in a chronic active hepatitis C patient receiving interferon-alpha therapy].
    Nihon Jinzo Gakkai shi, 1998, Volume: 40, Issue:2

    Topics: Aged; Anticoagulants; Antiviral Agents; Dipyridamole; Glomerulonephritis, Membranous; Heparin; Hepat

1998